Platinum-perovskite nanocomposite-based Exosensor for specific detection of prostate cancer in clinical settings

Dezhakam E., Mahmoudi E., Naseri A., Rahbarghazi R., IŞILDAK İ., Khalilzadeh B., ...More

Microchimica Acta, vol.191, no.10, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 191 Issue: 10
  • Publication Date: 2024
  • Doi Number: 10.1007/s00604-024-06655-z
  • Journal Name: Microchimica Acta
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Aqualine, Aquatic Science & Fisheries Abstracts (ASFA), Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, Food Science & Technology Abstracts, Metadex, Pollution Abstracts, Civil Engineering Abstracts
  • Keywords: Differential pulse voltammetry, Electrochemical Exosensor, Exosomes, Extracellular vesicles, Modified glassy carbon electrode, Perovskite, Prostate-specific antigen
  • Yıldız Technical University Affiliated: Yes

Abstract

Exosomes, extracellular vesicles (EVs) with an average size of 50–150 nm, transfer various biomolecules and exchange signaling molecules between cells in a paracrine manner. Molecular investigations have revealed that EVs can reflect real-time metabolic changes in normal- and cancer-origin cells and thus harbor valid diagnostic biomarkers. Despite these advantages, the detection of low concentrations of cancer cell EVs in biological fluids is still a great challenge. Here, a new electrochemical Exosensor based on platinum-perovskite is developed for the direct detection of EVs using a biotinylated monoclonal CD63 antibody as a capture element. The label-free method exhibited higher sensitivity with a lower limit of quantification of 2000 EVs/µL with a dynamic linear range (LDR) of 2000 to 14,000 EVs/μL compared with other available methods. To enhance the selectivity of detection, EVs were simultaneously sandwiched between secondary antibodies of PSA (prostate-specific antigen), as an FDA-approved prostate cancer biomarker. Data indicated that this Exosensor can distinguish normal and cancer EVs in samples from healthy individuals and prostate cancer patients. Taken together, this technology offers a unique approach to label-free quantification of EVs and cancer detection in the early stages. Graphical abstract: (Figure presented.).